Ruconest (conestat alfa)
- Region
- 🇪🇺 EU
- Active substance
- conestat alfa
- Company
- Pharming Group N.V.
- Status
- Authorised
- Therapeutic area
- Angioedemas, Hereditary
- EU approval
- Thu 28 Oct 2010
- Application
- EMEA/H/C/001223
- ATC
- B06AC04
- Official record
- www.ema.europa.eu
Indication
Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency.
Regulatory milestones
No milestones recorded in the last year.
Follow Ruconest
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.